Quick Answer
Vivos Therapeutics, Inc. reported Total Revenue of $15.03 million for fiscal year 2024.
Vivos Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2024 | $15.03M | +8.9% |
| 2023 | $13.80M | -13.9% |
| 2022 | $16.02M | -5.1% |
| 2021 | $16.89M | +29.2% |
| 2020 | $13.07M | +14.7% |
| 2019 | $11.39M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.78M | +75.7% | +77.6% |
| June 30, 2025 | $3.82M | -5.8% | +26.7% |
| March 31, 2025 | $3.02M | -11.8% | -21.9% |
| September 30, 2024 | $3.86M | +16.9% | -4.8% |
| June 30, 2024 | $4.05M | +19.4% | +18.6% |
| March 31, 2024 | $3.42M | -11.4% | +3.6% |
| September 30, 2023 | $3.30M | -22.3% | -2.8% |
| June 30, 2023 | $3.40M | -18.9% | -12.0% |
- Vivos Therapeutics, Inc. showed an increase of +8.9% in Total Revenue compared to the prior fiscal year.
- Over the 2019–2024 period, Vivos Therapeutics, Inc.’s total revenue has grown by 31.9% (from $11.39 million to $15.03 million).
- The most recent figure is from Vivos Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: